Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib + Trametinib in BRAF-refractory Melanoma
NCT01619774Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2012
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2012; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01619774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01619774.